Wealth Enhancement Advisory Services
TSHA icon

Wealth Enhancement Advisory Services’s Taysha Gene Therapies TSHA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.4K Buy
+10,026
New +$57.8K ﹤0.01% 4055

Other funds holding TSHA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $169M AUM 17.63% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's TSHA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Taysha Gene Therapies (TSHA) in Q3 2026: 10,026 shares worth $44.4K. The stake represents ﹤0.01% of the portfolio and ranks #4055 among its holdings.

7 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.

  • Wealth Enhancement Advisory Services held 10,026 shares of Taysha Gene Therapies worth $44.4K as of Q3 2026.
  • Taysha Gene Therapies was a new Wealth Enhancement Advisory Services position in Q3 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4055 holding.
  • 7 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.